Objective
This project has been designed in order to contribute to the development of a novel technology consisting to use bacteriophage lytic enzymes as agents for controlling bacterial populations on human mucosal membranes. These tissues are the reservoir for man y pathogenic bacteria found in the environment (i.e. pneumococci, staphylococci, streptococci). In most instances, it is this mucosal reservoir that is the focus of infection in the population. By reducing or eliminating this reservoir of pathogens in the community and controlled environments (i.e. hospitals and nursing homes), the incidence of disease will be markedly reduced. Because of the fear of developing resistances, antibiotics are not indicated. Thus, lytic enzymes may provide a good alternative. Cpl-1, a pneumococcal phage lysozyme has been chosen as a model. S. pneumoniae is a leading cause of acute otitis media, meningitis, pneumoniae, and sepsis. It is becoming increasingly resistant to multiple classes of antimicrobial agents. Because the hal f-life of Cpl-1 in the blood of mice is relatively short and is thought to be insufficient to obtain complete eradication of pneumococci, we propose to encapsulate it into liposomes. During the outgoing period, the antimicrobial activity and the residence time on mucosal membrane of different liposomal preparations will be tested in mice. The acquired knowledge will then be applied, in the laboratory of the return host, in order to develop a phase I human clinical trial with the more effective combination.
This project will be a great asset to the scientific career of the candidate, providing him all the necessary tools to develop his own infectious disease program. Moreover, the project will significantly increase the scientific expertise and attractiveness of the European Research Area. In fact, it is the first time that a bacteriophage lytic enzyme is proposed for human clinical trials.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences nursing
- natural sciences biological sciences microbiology virology
- medical and health sciences health sciences infectious diseases
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs antibiotics
- natural sciences biological sciences biochemistry biomolecules proteins enzymes
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2005-MOBILITY-6
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
OIF - Marie Curie actions-Outgoing International Fellowships
Coordinator
LAUSANNE
Switzerland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.